Loading
Major Depression Disorders / Transcranial Direct Current Stimulation (tDCS) / Major Depression · Interventional Study
ClinicalTrials.gov · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned safety and tolerability trial of accelerated high-dose transcranial direct current stimulation in people with major depression. The study employs a dose-escalation design starting at 2 mA and rising to 6 mA, with primary endpoints focused on device-related serious adverse events, session completion, and adverse event questionnaire scores. No results have been posted in this registry record.
Interventional, Single Group, Open label, Treatment purpose. Major Depression, Major Depression Disorders; age from 18 Years; to 70 Years. Intervention: Experimental: High-Dose tDCS Intervention. n = 20. 1 site: United States.
This is a planned safety and tolerability trial of accelerated high-dose transcranial direct current stimulation in people with major depression. The study employs a dose-escalation design starting at 2 mA and rising to 6 mA, with primary endpoints focused on device-related serious adverse events, session completion, and adverse event questionnaire scores. No results have been posted in this registry record.
No control or comparator arm specified; this is a safety run-in with dose escalation, not a powered efficacy trial. Small sample size (N=20 estimated) limits generalizability of safety findings.
Clinicians should note this is a safety and tolerability study only, with no efficacy data or results currently available. Results, when posted, will inform whether accelerated high-dose tDCS can be pursued safely in future efficacy trials.
Registry record of an active, non-results-reporting safety and tolerability study of accelerated high-dose tDCS in depression; no efficacy or outcome data are posted.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should note this is a safety and tolerability study only, with no efficacy data or results currently available. Results, when posted, will inform whether accelerated high-dose tDCS can be pursued safely in future efficacy trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07226011). This is a study registration, not published results. Lead sponsor: Medical University of South Carolina. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 20 participants (ESTIMATED). Conditions: Major Depression, Major Depression Disorders. Interventions: DEVICE: Transcranial Direct Current Stimulation (tDCS). Primary outcome measures: Number of Participants With Device-Related Serious Adverse Events , Up to 7 days; Number of Participants Completing All Scheduled Sessions Without Discontinuation , Completion of all planned stimulation sessions without dropout due to adverse effects.; Mean Score on Adverse Event Questionnaire , Daily during treatment (Days 1-5). Brief summary: In this study, investigators are testing whether a higher dose of a non-invasive brain stimulation technique, called transcranial direct current stimulation (tDCS), can be safely used in people with depression. Participants will come to the Brain Stimulation Lab and receive mild electrical stimulation through electrodes placed on their scalp. The study begins with a safety run-in, where the first few participants will receive stimulation at gradually increasing levels (2, 4, and 6 milliamps) while being closely monitored. If no serious side effects are found, later participants will receive repeated 6 milliamp sessions for 5 days total. Investigators will check skin comfort, mood, and overall tolerability after each session.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.